Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178

Core Insights - Biogen Inc. (NASDAQ:BIIB) is recognized as a strong investment opportunity by hedge funds, with multiple analysts raising their price targets following positive fiscal Q4 and full year 2025 results [1][2][3] Price Target Adjustments - Wedbush raised its price target for Biogen to $187 from $178 while maintaining a Neutral rating, highlighting the company's top- and bottom-line performance but noting the lack of revenue growth drivers [1] - RBC Capital increased its price target to $233 from $217, keeping an Outperform rating, citing stability and predictability in the company's performance and a solid foundation for future growth [2] - BMO Capital revised its price target to $196 from $165, maintaining a Market Perform rating after the fiscal Q4 earnings beat [3] Company Overview - Biogen is a global biopharmaceutical company focused on discovering, developing, and delivering therapies for serious diseases, including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, and amyotrophic lateral sclerosis [4] - The company's marketed product portfolio includes treatments for multiple sclerosis such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, as well as SPINRAZA for spinal muscular atrophy and SKYCLARYS for Friedreich's Ataxia [4]